News
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
1d
The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo ...
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...
"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Investigative Journalism Foundation on MSN3d
A diabetes drug company and charity are lobbying the Saskatchewan government as Ottawa promises to follow through on pharmacareEli Lilly, Diabetes Canada both lobbying in Saskatchewan as the province continues to be non-committal on pharmacare deals ...
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback